昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06127 昭衍新药

交易中 09-04 13:27:49

23.080

-0.540

-2.29%

最高24.080	最低22.940	成交量180.87万
今开23.800	昨收23.620	日振幅4.83%
总市值172.87亿	流通市值27.46亿	总股本7.49亿
成交额4,249万	换手率1.52%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06127","market":"HK","secType":"STK","nameCN":"昭衍新药","latestPrice":23.08,"timestamp":1788499624493,"preClose":23.62,"halted":0,"volume":1808700,"delay":0,"changeRate":-0.022861981371718996,"floatShares":118995206,"shares":749000000,"eps":0.46703987706010575,"marketStatus":"交易中","change":-0.54,"latestTime":"09-04 13:27:49","open":23.8,"high":24.08,"low":22.94,"amount":42491510,"amplitude":0.048264,"askPrice":23.1,"askSize":1000,"bidPrice":23.06,"bidSize":4600,"shortable":3,"etf":0,"ttmEps":1.5584571925640183,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788509400000},"marketStatusCode":2,"adr":0,"listingDate":1614268800000,"exchange":"SEHK","adjPreClose":23.62,"dividendRate":0.006048,"openAndCloseTimeList":[[1788485400000,1788494400000],[1788498000000,1788508800000]],"volumeRatio":0.873253,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"603127","market":"SH","secType":"STK","nameCN":"昭衍新药","latestPrice":43.46,"timestamp":1788499666000,"preClose":44.6,"halted":0,"volume":17568400,"delay":0,"premium":"-54.52"}},"requestUrl":"/m/hq/s/06127/wiki","defaultTab":"wiki","newsList":[{"id":"2664681762","title":"昭衍新药（603127）披露8月证券变动月报表，9月2日股价下跌1.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664681762","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664681762?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:10","pubTimestamp":1788358228,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，昭衍新药报收于44.6元，较前一交易日下跌1.28%，最新总市值为334.21亿元。该股当日开盘45.18元，最高45.66元，最低44.03元，成交额达12.86亿元，换手率为4.58%。近日，公司发布H股公告《8月月报表》。公司确认2026年8月无股份增减，公众持股量符合上市规则要求，且所有证券发行事项均已获董事会批准并遵守相关法规。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200042690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","06127","161027","BK1576","603127","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125091652","title":"昭衍新药更新2026年8月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1125091652","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125091652?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:11","pubTimestamp":1788336680,"startTime":"0","endTime":"0","summary":"北京昭衍新药研究中心股份有限公司于2026年9月2日发布了截至2026年8月31日止的股份变动月报表，集中披露公司本月股本结构及股份变动情况。月报显示，截至2026年8月31日，公司已发行股本仍为人民币749,348,220元，包含H股118,995,206股及A股630,353,014股。公司确认已遵守香港联交所证券上市规则及其他适用法律法规的相关规定。公告由联席公司秘书高大鹏于2026年9月2日签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193092650","title":"异动解读｜昭衍新药盘中下跌5.07%，中报利润暴增但主业仍亏持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1193092650","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1193092650?lang=zh_cn&edition=full","pubTime":"2026-09-01 14:19","pubTimestamp":1788243582,"startTime":"0","endTime":"0","summary":"9月1日，昭衍新药盘中下跌5.07%，报23.22港元，成交额7123.68万港元。消息面上，公司8月28日发布中报，归母净利润7.48亿元，同比暴增1126.8%，但营收仅7.04亿元，同比增长5.27%。市场对\"账面浮盈\"驱动的利润可持续性存疑，资金延续获利了结。值得注意的是，当日同板块金斯瑞生物科技涨7.38%、英矽智能涨4.44%，昭衍新药走势明显偏弱，反映市场对其盈利质量的独立定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"昭衍新药盘中走低，利润暴增难掩主业亏损","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129712145","title":"昭衍新药（06127）续租北京大兴研发办公物业　三年总租金约855万元","url":"https://stock-news.laohu8.com/highlight/detail?id=1129712145","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1129712145?lang=zh_cn&edition=full","pubTime":"2026-08-31 12:06","pubTimestamp":1788149219,"startTime":"0","endTime":"0","summary":"2026年8月28日，昭衍新药发布公告称，公司及其全资附属公司昭衍（北京）检测技术有限公司、北京昭衍药物检定研究有限公司分别与关联方北京昭衍生物技术有限公司及其附属公司签署三份《租赁协议》，继续承租位于北京市大兴区瑞合西一路7号的部分设施，租期自2026年9月1日至2029年8月31日，为期3年。1）昭衍新药租赁面积2,212平方米；其余董事一致同意租赁协议条款公平合理，符合公司及股东整体利益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149026821","title":"异动解读｜昭衍新药盘中下跌5.06%，中报利润暴增但主业仍亏引发市场抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1149026821","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149026821?lang=zh_cn&edition=full","pubTime":"2026-08-31 11:13","pubTimestamp":1788146033,"startTime":"0","endTime":"0","summary":"8月31日，昭衍新药盘中下跌5.06%，报24.02港元，成交额7527.36万港元。消息面上，公司8月28日发布中报，归母净利润7.48亿元，同比暴增1126.8%，但营收仅7.04亿元，同比增长仅5.27%。剔除该因素后，公司实验室服务及其他业务净利润为-3661万元，仍处于亏损状态。此外，整个生命科学工具和服务板块同日普遍走弱，药明生物跌5.27%、金斯瑞生物科技跌5.43%、英矽智能跌6.65%，行业情绪承压加剧个股跌幅。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"昭衍新药盘中重挫，纸面利润难撑股价","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663048925","title":"昭衍新药（603127）2026年中报简析：营收净利润同比双双增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2663048925","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663048925?lang=zh_cn&edition=full","pubTime":"2026-08-30 06:11","pubTimestamp":1788041472,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期昭衍新药发布2026年中报。根据财报显示，昭衍新药营收净利润同比双双增长。截至本报告期末，公司营业总收入7.04亿元，同比上升5.27%，归母净利润7.48亿元，同比上升1126.8%。本文数据来源于昭衍新药2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000002130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010890","title":"每周股票复盘：昭衍新药（603127）Q2净利同比增2469.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010890","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010890?lang=zh_cn&edition=full","pubTime":"2026-08-30 01:26","pubTimestamp":1788024370,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，昭衍新药报收于47.54元，较上周的49.27元下跌3.51%。本周关注点业绩披露要点：2026年第二季度归母净利润5.09亿元，同比上升2469.84%。业绩披露要点昭衍新药2026年中报显示，上半年度公司主营收入7.04亿元，同比上升5.27%；归母净利润7.48亿元，同比上升1126.8%；扣非净利润6.99亿元，同比上升2931.69%。第二季度单季度主营收入3.88亿元，同比上升1.69%；单季度归母净利润5.09亿元，同比上升2469.84%；单季度扣非净利润4.81亿元，同比上升18544.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000000512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK0216","BK1576","BK1141","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662833099","title":"昭衍新药（603127）披露召开2026年半年度业绩说明会公告，8月28日股价下跌1.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662833099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662833099?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:02","pubTimestamp":1787925731,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，昭衍新药报收于47.54元，较前一交易日下跌1.25%，最新总市值为356.24亿元。该股当日开盘48.0元，最高51.51元，最低47.5元，成交额达18亿元，换手率为5.88%。公司将于2026年9月8日9:00-10:00通过上证路演中心网络互动方式召开2026年半年度业绩说明会，介绍公司半年度经营成果及财务状况。投资者可于2026年9月1日至9月7日16:00前通过上证路演中心网站或公司邮箱提交问题。说明会结束后可通过该平台查看会议内容。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800053403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1576","06127","BK0216","BK1141","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102160469","title":"昭衍新药(06127)发布2026年中期业绩：净利润7.48亿元同比增逾11倍  在手订单达37亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102160469","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102160469?lang=zh_cn&edition=full","pubTime":"2026-08-28 19:03","pubTimestamp":1787915014,"startTime":"0","endTime":"0","summary":"2026年8月29日，昭衍新药披露2026年半年度报告。期内，公司实现营业收入7.04亿元，同比增长5.27%；归属于上市公司股东的净利润7.48亿元，同比大幅增长1,126.80%；扣非后净利润6.99亿元，同比增长2,931.69%。截至2026年6月30日，公司总资产达108.26亿元，较上年末增长11.82%；归属于上市公司股东的净资产为89.75亿元，同比增长7.81%。经营活动产生的现金流量净额4.57亿元，同比增加180.89%。基本每股收益1.00元，而上年同期为0.08元。截至报告期末，公司资产负债率为17.10%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066223","title":"昭衍新药(06127)公布中期业绩 股东应占溢利约7.48亿元 同比增长约11.27倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066223","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066223?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:54","pubTimestamp":1787910886,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昭衍新药(06127)公布2026年中期业绩，收益约7.04亿元，同比增长5.3%;公司权益股东应占期内溢利约7.48亿元，同比增长约11.27倍;每股盈利1元。报告期内，公司整体在手订单金额约为37亿元，同比增长60.9%;新签订单金额约为20.2亿元，同比增长98.0%。公告称，净利润增加主要是由于生物资产公平值变动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603127","BK1141","BK0216","06127","BK1576"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133302289","title":"昭衍新药2026年上半年营收7.04亿元，净利润7.48亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133302289","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133302289?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:43","pubTimestamp":1787910198,"startTime":"0","endTime":"0","summary":"2026年上半年，昭衍新药实现营业收入7.04亿元，同比增长5.3%。毛利为1.45亿元，同比增长38.0%，毛利率由上年同期的15.7%提升至20.6%。期内净利润达7.48亿元，同比大幅增长1126.8%。在成本端，服务成本约5.59亿元，同比轻微下降0.8%。非临床研究服务在上半年收入6.76亿元，占总营收比重96.0%；临床试验及相关服务收入为27.74百万元，占总营收比重3.9%；销售实验模型收入0.18百万元，占总营收比重0.1%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昭衍新药2026年上半年营收7.04亿元，净利润7.48亿元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662306602","title":"昭衍新药：上半财年净利润同比增长1126.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662306602","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662306602?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:43","pubTimestamp":1787910180,"startTime":"0","endTime":"0","summary":"南财智讯8月28日电，昭衍新药（06127.HK）公告，公司截至2026年6月30日止六个月实现营业收入70381.90万元，同比增长5.27%；净利润74750.00万元，同比增长1126.8%；基本及摊薄每股收益均为1.00元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608283858311650.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608283858311650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662806816","title":"昭衍新药：2026年上半年净利7.48亿元 同比增1126.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662806816","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662806816?lang=zh_cn&edition=full","pubTime":"2026-08-28 16:55","pubTimestamp":1787907355,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1141","BK0216","BK1576","06127","603127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184175451","title":"异动解读｜昭衍新药盘中上涨5.16%，CXO板块集体反弹叠加中报披露在即","url":"https://stock-news.laohu8.com/highlight/detail?id=1184175451","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184175451?lang=zh_cn&edition=full","pubTime":"2026-08-25 13:03","pubTimestamp":1787634234,"startTime":"0","endTime":"0","summary":"8月25日，昭衍新药盘中上涨5.16%，报25.26港元，成交额7207.13万港元。消息面上，公司将于8月28日召开董事会审议中期业绩。此外，截至一季度末公司在手订单31亿元，非人灵长类实验动物价格与签约价格均有所回升，行业景气度上行信号持续验证。8月24日该股曾随板块回调逾5%，今日伴随CXO板块集体修复出现技术性反弹。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"昭衍新药盘中上涨，CXO板块集体反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661622126","title":"8月24日昭衍新药跌5.85%，广发医疗保健股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661622126","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661622126?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:31","pubTimestamp":1787560265,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日昭衍新药跌5.85%，收盘报46.39元，换手率5.86%，成交量36.79万手，成交额17.38亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共40家，其中持有数量最多的公募基金为广发基金的广发医疗保健股票A。广发医疗保健股票A目前规模为35.24亿元，最新净值1.9538，较上一交易日下跌3.58%，近一年下跌6.23%。广发医疗保健股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400021780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","06127","BK1576","603127","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110708615","title":"异动解读｜昭衍新药盘中下跌5.22%，CXO板块集体重挫叠加中报前博弈加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=1110708615","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110708615?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:53","pubTimestamp":1787540039,"startTime":"0","endTime":"0","summary":"8月24日，昭衍新药盘中下跌5.22%，报23.98港元，成交额4770.47万港元。所在生命科学工具和服务板块全线走弱，药明生物跌5.25%、药明合联跌5.02%、药明康德跌4.81%、金斯瑞生物科技跌4.76%，板块联动拖累明显。消息面上，公司将于8月28日召开董事会审议中期业绩。叠加近日资金持续净流出，市场对业绩含金量的分歧在中报披露前集中释放。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"昭衍新药走弱，中报博弈前资金出逃","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661321132","title":"每周股票复盘：昭衍新药（603127）将发布中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2661321132","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661321132?lang=zh_cn&edition=full","pubTime":"2026-08-23 01:05","pubTimestamp":1787418313,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，昭衍新药报收于49.27元，较上周的51.3元下跌3.96%。本周，昭衍新药8月20日盘中最高价报54.78元。公司公告汇总H股公告：董事会召开日期北京昭衍新药研究中心股份有限公司董事会谨定于2026年8月28日举行董事会会议，以考虑及通过本集团截至2026年6月30日止六个月中期业绩，并处理其他事项。本次会议由董事会主席冯宇霞召集，于2026年8月18日在中国北京发布公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK1576","BK1141","06127","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162963461","title":"财报前瞻 ｜昭衍新药本季度营收预期待披露，机构倾向正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1162963461","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162963461?lang=zh_cn&edition=full","pubTime":"2026-08-21 10:28","pubTimestamp":1787279319,"startTime":"0","endTime":"0","summary":"昭衍新药将于2026年08月28日盘后披露中期业绩，围绕订单兑现与价格修复的进展成为市场关注重点。市场一致预期尚未形成关于本季度营收、毛利率与净利润的量化预测，公司层面也未披露明确口径；就每股收益维度，当前工具口径显示本季度调整后每股收益预计为0.48元，同比增长317.39%，其他预测项暂无披露。鉴于上季度净利率为75.40%，本季度需关注一次性与公允价值变动的影响，并剔除非经常性因素以观察可持续盈利质量。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜昭衍新药本季度营收预期待披露，机构倾向正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660801992","title":"昭衍新药（603127）披露与专业投资机构合作参与投资基金的进展公告，8月20日股价上涨5.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660801992","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660801992?lang=zh_cn&edition=full","pubTime":"2026-08-20 22:00","pubTimestamp":1787234456,"startTime":"0","endTime":"0","summary":"截至2026年8月20日收盘，昭衍新药报收于52.57元，较前一交易日上涨5.56%，最新总市值为393.93亿元。该股当日开盘52.0元，最高54.78元，最低49.5元，成交额达36.9亿元，换手率为11.22%。上述基金已完成中国证券投资基金业协会的备案登记。公司将持续关注基金运作情况并履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000044559.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603127","BK1141","BK0216","BK1576","06127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163568160","title":"昭衍新药（06127）两支参投基金完成私募备案　累计基金出资额达7.57亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1163568160","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163568160?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:11","pubTimestamp":1787217099,"startTime":"0","endTime":"0","summary":"2026年8月21日，北京昭衍新药研究中心股份有限公司发布海外监管公告，披露其与专业投资机构合作参与投资的两支基金——“深圳市倚锋明远种子创业投资合伙企业”及“北京生命科学园贰期创业投资基金管理中心”已在中国证券投资基金业协会完成私募投资基金备案登记，分别取得备案编码“SEF368”和“SAQB69”。截至本公告披露日，昭衍新药已累计参与9只私募股权投资基金，人民币出资总额为75,740万元，另向“Pablo Hill Venture Fund One, L.P.”认缴800万美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0852},{"period":"1month","weight":0.0129},{"period":"3month","weight":0.4005},{"period":"6month","weight":0.1833},{"period":"1year","weight":0.0581},{"period":"ytd","weight":0.1557}],"compareEarnings":[{"period":"1week","weight":-0.0138},{"period":"1month","weight":-0.0247},{"period":"3month","weight":0.0101},{"period":"6month","weight":-0.0211},{"period":"1year","weight":-0.0051},{"period":"ytd","weight":-0.0163}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"北京昭衍新药研究中心股份有限公司是一家主要从事新药药理毒理学研究的中国公司。该公司通过三个分部开展业务。药物非临床研究服务分部主要提供药品非临床安全性评价服务、药效学研究服务、药代动力学研究服务。临床服务及其他分部主要提供药品上市前的临床服务以及药物警戒服务。实验模型供应分部为实验模型及其附属产品的生产和销售。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.052852},{"month":2,"riseRate":0.6,"avgChangeRate":0.086368},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.020373},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.07562},{"month":5,"riseRate":0.666667,"avgChangeRate":0.065576},{"month":6,"riseRate":0.666667,"avgChangeRate":0.063039},{"month":7,"riseRate":0.833333,"avgChangeRate":0.119134},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.109974},{"month":9,"riseRate":0.5,"avgChangeRate":0.007785},{"month":10,"riseRate":0.2,"avgChangeRate":-0.062964},{"month":11,"riseRate":0.4,"avgChangeRate":0.019565},{"month":12,"riseRate":0.6,"avgChangeRate":0.001933}],"exchange":"SEHK","name":"昭衍新药","nameEN":"JOINN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"昭衍新药,06127,昭衍新药股票,昭衍新药股票老虎,昭衍新药股票老虎国际,昭衍新药行情,昭衍新药股票行情,昭衍新药股价,昭衍新药股市,昭衍新药股票价格,昭衍新药股票交易,昭衍新药股票购买,昭衍新药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"昭衍新药(06127)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供昭衍新药(06127)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}